[6-K] ASTRAZENECA PLC Current Report (Foreign Issuer)

Rhea-AI Filing Summary

AstraZeneca PLC reported a director/PDMR shareholding notification: Non-Executive Director Karen Knudsen acquired 9 American Depositary Shares (ADSs) on 9 September 2025 through reinvestment of the first interim dividend for the year ending 31 December 2025, which the company paid on 8 September 2025. Two ADSs equal one ordinary share of $0.25 each. The reported transaction price per ADS was $81.0499. The disclosure was made on 25 September 2025 and follows the EU Market Abuse Regulation reporting requirements.

Positive

• Compliance disclosure completed under EU Market Abuse Regulation reporting rules
• Dividend reinvestment used to acquire ADSs, signaling participation in the company's dividend program

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Routine director dividend reinvestment disclosed; minimal governance impact.

The notification documents a standard dividend reinvestment by a Non-Executive Director, resulting in the acquisition of 9 ADSs. This is a compliance-focused disclosure that demonstrates adherence to EU Market Abuse Regulation reporting obligations. The transaction size is small and was effected via dividend reinvestment rather than market purchase, so it conveys limited new information about insider sentiment or material ownership change.

Financial Analyst

TL;DR: Small, routine share acquisition via dividend reinvestment; negligible market or financial impact.

The acquisition price reported is $81.0499 per ADS, and the purchase of 9 ADSs (equivalent to 4.5 ordinary shares) is immaterial relative to AstraZeneca's market capitalization. Because the shares were obtained through reinvested dividends paid on 8 September 2025, this reflects standard shareholder activity rather than an open-market investment decision by management. No earnings, financing, or strategic changes are disclosed in this filing.

09/25/2025 - 01:27 PM

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of September 2025

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Director/PDMR Shareholding

25 September 2025

Transaction by Person Discharging Managerial Responsibilities

AstraZeneca PLC (the Company) announces that it was notified on 25 September 2025 that Karen Knudsen, Non-Executive Director, had acquired 9 American Depositary Shares (ADSs) in the Company on 9 September 2025, pursuant to the reinvestment of the first interim dividend in respect of the year ending 31 December 2025, paid by the Company on 8 September 2025. Two ADSs are equivalent to one of the Company's ordinary shares of $0.25 each.

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (since it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Karen Knudsen
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	AstraZeneca PLC American Depositary Shares CUSIP: 0463531089
b)	Nature of the transaction	Acquisition of AstraZeneca PLC American Depositary Shares through the reinvestment of the first interim dividend of the Company, in respect of the year ending 31 December 2025, paid by the Company on 8 September 2025.
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		$81.0499	9.0737
d)	Aggregated information - Aggregated volume - Price	Not applicable - single transaction
e)	Date of the transaction	9 September 2025
f)	Place of the transaction	XNAS

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 25 September 2025

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary

FAQ

What transaction did AstraZeneca (AZN) disclose in this Form 6-K?

The company disclosed that Non-Executive Director Karen Knudsen acquired 9 ADSs on 9 September 2025 via reinvestment of the first interim dividend paid on 8 September 2025.

How many ordinary shares do 9 ADSs represent for AZN?

Two ADSs are equivalent to one ordinary share, so 9 ADSs represent 4.5 ordinary shares.

What price was reported for the ADS acquisition?

The reported price was $81.0499 per ADS.

Does this Form 6-K indicate any change to AstraZeneca's earnings or strategy?

No. The filing only reports a director shareholding transaction via dividend reinvestment and does not contain earnings, strategic announcements, or financial statements.

When was the dividend paid that funded the reinvestment?

The dividend was paid on 8 September 2025, and the ADS acquisition occurred on 9 September 2025.